Changes in biventricular myocardial function after six months of ixekizumab therapy in patients with psoriatic arthritis: a prospective speckle-tracking echocardiographic study.
Nikolaos Kougkas, Dimitrios Deligeorgakis, George Koulaouzidis, Pinelopi Giannakopoulou, Nikolaos Antoniou, Ioannis Zarifis, Evdokia Papadimitriou, Theodoros Dimitroulas, Adam Tsaousidis
{"title":"Changes in biventricular myocardial function after six months of ixekizumab therapy in patients with psoriatic arthritis: a prospective speckle-tracking echocardiographic study.","authors":"Nikolaos Kougkas, Dimitrios Deligeorgakis, George Koulaouzidis, Pinelopi Giannakopoulou, Nikolaos Antoniou, Ioannis Zarifis, Evdokia Papadimitriou, Theodoros Dimitroulas, Adam Tsaousidis","doi":"10.1007/s00296-026-06332-9","DOIUrl":null,"url":null,"abstract":"<p><p>To evaluate longitudinal changes in conventional and speckle-tracking echocardiographic indices in patients with psoriatic arthritis (PsA) who achieved a disease activity index for psoriatic arthritis (DAPSA)-defined clinical response during ixekizumab therapy.In this prospective single-centre observational cohort, 21 adults with PsA underwent clinical, laboratory and transthoracic echocardiographic assessment before ixekizumab initiation and after 6 months of treatment. The principal echocardiographic outcome was the within-patient change in absolute left vetricle global longitudinal strain (LV GLS) between baseline and 6 months. Secondary echocardiographic outcomes included right ventricle (RV) GLS, left ventricular ejection fraction (LVEF), tricuspid annular plane systolic excursion (TAPSE), tricuspid annular systolic velocity (RV S') and tricuspid E to E' ratio (E/E'), while clinical secondary outcomes included DAPSA, body surface area (BSA), minimal disease activity (MDA), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Mean age was 49.6 ± 11.6 years, 57.1% were male and 11 patients (52.4%) were biologic-naïve. MDA was achieved by 17 patients (81.0%). DAPSA decreased from 28.9 ± 4.3 to 7.7 ± 4.2, accompanied by reductions in CRP and ESR (all p < 0.001). Absolute LV GLS increased from 18.5 ± 1.3% to 20.5 ± 1.9% (mean change 2.0%, 95% CI 1.49-2.51; p < 0.001), while absolute RV GLS increased from 21.5 ± 3.3% to 25.8 ± 4.2% (mean change 4.29%, 95% CI 3.37-5.20; p < 0.001). LVEF, TAPSE, RV S' and E/E' also improved significantly. Although DAPSA reduction correlated with increased LVEF, while BSA reduction with increased LV GLS and TAPSE, these associations were exploratory and should be interpreted cautiously. Among patients with PsA who achieved clinical response to ixekizumab, 6 months of treatment was accompanied by improvements in left- and right-ventricular functional indices. Because the cohort was small, responder-enriched and lacked a comparator group, these findings should be considered hypothesis-generating and require confirmation in larger controlled studies.</p>","PeriodicalId":21322,"journal":{"name":"Rheumatology International","volume":"46 11","pages":""},"PeriodicalIF":3.5000,"publicationDate":"2026-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rheumatology International","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00296-026-06332-9","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
To evaluate longitudinal changes in conventional and speckle-tracking echocardiographic indices in patients with psoriatic arthritis (PsA) who achieved a disease activity index for psoriatic arthritis (DAPSA)-defined clinical response during ixekizumab therapy.In this prospective single-centre observational cohort, 21 adults with PsA underwent clinical, laboratory and transthoracic echocardiographic assessment before ixekizumab initiation and after 6 months of treatment. The principal echocardiographic outcome was the within-patient change in absolute left vetricle global longitudinal strain (LV GLS) between baseline and 6 months. Secondary echocardiographic outcomes included right ventricle (RV) GLS, left ventricular ejection fraction (LVEF), tricuspid annular plane systolic excursion (TAPSE), tricuspid annular systolic velocity (RV S') and tricuspid E to E' ratio (E/E'), while clinical secondary outcomes included DAPSA, body surface area (BSA), minimal disease activity (MDA), C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Mean age was 49.6 ± 11.6 years, 57.1% were male and 11 patients (52.4%) were biologic-naïve. MDA was achieved by 17 patients (81.0%). DAPSA decreased from 28.9 ± 4.3 to 7.7 ± 4.2, accompanied by reductions in CRP and ESR (all p < 0.001). Absolute LV GLS increased from 18.5 ± 1.3% to 20.5 ± 1.9% (mean change 2.0%, 95% CI 1.49-2.51; p < 0.001), while absolute RV GLS increased from 21.5 ± 3.3% to 25.8 ± 4.2% (mean change 4.29%, 95% CI 3.37-5.20; p < 0.001). LVEF, TAPSE, RV S' and E/E' also improved significantly. Although DAPSA reduction correlated with increased LVEF, while BSA reduction with increased LV GLS and TAPSE, these associations were exploratory and should be interpreted cautiously. Among patients with PsA who achieved clinical response to ixekizumab, 6 months of treatment was accompanied by improvements in left- and right-ventricular functional indices. Because the cohort was small, responder-enriched and lacked a comparator group, these findings should be considered hypothesis-generating and require confirmation in larger controlled studies.
期刊介绍:
RHEUMATOLOGY INTERNATIONAL is an independent journal reflecting world-wide progress in the research, diagnosis and treatment of the various rheumatic diseases. It is designed to serve researchers and clinicians in the field of rheumatology.
RHEUMATOLOGY INTERNATIONAL will cover all modern trends in clinical research as well as in the management of rheumatic diseases. Special emphasis will be given to public health issues related to rheumatic diseases, applying rheumatology research to clinical practice, epidemiology of rheumatic diseases, diagnostic tests for rheumatic diseases, patient reported outcomes (PROs) in rheumatology and evidence on education of rheumatology. Contributions to these topics will appear in the form of original publications, short communications, editorials, and reviews. "Letters to the editor" will be welcome as an enhancement to discussion. Basic science research, including in vitro or animal studies, is discouraged to submit, as we will only review studies on humans with an epidemological or clinical perspective. Case reports without a proper review of the literatura (Case-based Reviews) will not be published. Every effort will be made to ensure speed of publication while maintaining a high standard of contents and production.
Manuscripts submitted for publication must contain a statement to the effect that all human studies have been reviewed by the appropriate ethics committee and have therefore been performed in accordance with the ethical standards laid down in an appropriate version of the 1964 Declaration of Helsinki. It should also be stated clearly in the text that all persons gave their informed consent prior to their inclusion in the study. Details that might disclose the identity of the subjects under study should be omitted.